BioAtla Plans 50-for-1 Share Consolidation and Reports $9.8M Loss
BioAtla will enact a 50-for-1 share consolidation on April 6 to regain Nasdaq’s $1 minimum bid requirement and adopt CUSIP 09077B203. The company posted Q4 R&D expenses of $8 million, a $9.8 million net loss, and $7.1 million cash, launching a strategic review and asset monetization process.
1. Share Consolidation Details
BioAtla will effect a 50-for-1 share consolidation of its common stock effective April 6 at 12:01 a.m. Eastern Time, converting every 50 shares into one post-consolidation share with new CUSIP 09077B203, aiming to meet the $1 minimum bid requirement for continued Nasdaq listing.
2. Fourth Quarter Financial Performance
In Q4 2025, R&D expenses decreased to $8.0 million from $11.7 million a year ago, while net loss narrowed to $9.8 million; collaboration revenue was $2.0 million. Cash and cash equivalents stood at $7.1 million as of December 31, 2025.
3. Strategic Review and Cash Runway
The board engaged Tungsten Advisors to explore strategic alternatives including asset sales, licensing deals and partnerships, implemented workforce reductions and cost cuts, and is using a Standby Equity Purchase Agreement to extend runway through the formal strategic review process.